1. Home
  2. HOWL vs LICN Comparison

HOWL vs LICN Comparison

Compare HOWL & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • LICN
  • Stock Information
  • Founded
  • HOWL 2017
  • LICN 2004
  • Country
  • HOWL United States
  • LICN China
  • Employees
  • HOWL N/A
  • LICN N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • LICN
  • Sector
  • HOWL Health Care
  • LICN
  • Exchange
  • HOWL Nasdaq
  • LICN Nasdaq
  • Market Cap
  • HOWL 87.4M
  • LICN 8.7M
  • IPO Year
  • HOWL 2021
  • LICN 2023
  • Fundamental
  • Price
  • HOWL $1.49
  • LICN $0.07
  • Analyst Decision
  • HOWL Strong Buy
  • LICN
  • Analyst Count
  • HOWL 2
  • LICN 0
  • Target Price
  • HOWL $9.50
  • LICN N/A
  • AVG Volume (30 Days)
  • HOWL 260.9K
  • LICN 16.4M
  • Earning Date
  • HOWL 03-06-2025
  • LICN 12-31-2024
  • Dividend Yield
  • HOWL N/A
  • LICN N/A
  • EPS Growth
  • HOWL N/A
  • LICN 36.90
  • EPS
  • HOWL N/A
  • LICN 0.28
  • Revenue
  • HOWL $3,386,000.00
  • LICN $41,929,000.00
  • Revenue This Year
  • HOWL N/A
  • LICN N/A
  • Revenue Next Year
  • HOWL $34.17
  • LICN N/A
  • P/E Ratio
  • HOWL N/A
  • LICN $0.24
  • Revenue Growth
  • HOWL N/A
  • LICN 24.86
  • 52 Week Low
  • HOWL $1.26
  • LICN $0.06
  • 52 Week High
  • HOWL $8.19
  • LICN $2.44
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 54.09
  • LICN 23.33
  • Support Level
  • HOWL $1.28
  • LICN $0.07
  • Resistance Level
  • HOWL $1.60
  • LICN $0.10
  • Average True Range (ATR)
  • HOWL 0.10
  • LICN 0.02
  • MACD
  • HOWL 0.03
  • LICN 0.02
  • Stochastic Oscillator
  • HOWL 67.65
  • LICN 3.92

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About LICN Lichen China Limited

Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.

Share on Social Networks: